Vera Magistroni

List of Publications by Year
in descending order

27 papers	1,834 citations	471509 17 h-index	526287 27 g-index
28 all docs	28 docs citations	28 times ranked	3035 citing authors

#	Article	IF	Citations
1	Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. Cancers, 2021, 13, 4422.	3.7	11
2	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. HemaSphere, 2020, 4, e497.	2.7	14
3	De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. Haematologica, 2019, 104, 1789-1797.	3.5	21
4	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nature Communications, 2018, 9, 2192.	12.8	66
5	OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes. Scientific Reports, 2017, 7, 46290.	3.3	31
6	The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition. Journal of Cancer, 2017, 8, 140-145.	2.5	12
7	Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis. Blood, 2016, 128, 3075-3075.	1.4	1
8	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood, 2015, 125, 499-503.	1.4	115
9	RNAâ€seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients. American Journal of Hematology, 2015, 90, E227-8.	4.1	2
10	BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. Molecular Cancer, 2015, 14, 132.	19.2	35
11	ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents. Oncotarget, 2015, 6, 16611-16622.	1.8	18
12	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nature Genetics, 2013, 45, 18-24.	21.4	359
13	Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex. Neoplasia, 2013, 15, 511-IN17.	5.3	44
14	Identification of novel point mutations in splicing sites integrating wholeâ€exome and <scp>RNA</scp>â€seq data in myeloproliferative diseases. Molecular Genetics & Genomic Medicine, 2013, 1, 246-259.	1.2	17
15	CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data. PLoS ONE, 2013, 8, e74825.	2.5	20
16	SETBP1 and CSF3R Mutations In Atypical Chronic Myeloid Leukemia. Blood, 2013, 122, 2598-2598.	1.4	1
17	FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery. Nucleic Acids Research, 2012, 40, e123-e123.	14.5	29
18	Three novel patientâ€derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. American Journal of Hematology, 2012, 87, E125-8.	4.1	93

#	Article	IF	Citations
19	Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia. Blood, 2012, 120, 3727-3727.	1.4	1
20	ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells. PLoS ONE, 2011, 6, e28162.	2.5	25
21	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood, 2010, 116, 3013-3022.	1.4	110
22	Colorectal Tumors Are Effectively Eradicated by Combined Inhibition of Î²-Catenin, KRAS, and the Oncogenic Transcription Factor ITF2. Cancer Research, 2010, 70, 7253-7263.	0.9	45
23	Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants. Journal of Clinical Oncology, 2009, 27, 469-471.	1.6	365
24	Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. International Journal of Cancer, 2009, 124, 1990-1996.	5.1	29
25	The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. Blood Cells, Molecules, and Diseases, 2006, 37, 111-115.	1.4	9
26	In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. Cancer Research, 2006, 66, 11314-11322.	0.9	352
27	Imatinib dose increase up to 1200â€‰mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. Leukemia, 2005, 19, 1985-1987.	7.2	9